Nudoxa PEG Dosage/Direction for Use

Important Use Information: Do not substitute doxorubicin hydrochloride liposome injection for other doxorubicin hydrochloride products.
Do not administer as an undiluted suspension or as an intravenous bolus.
Ovarian Cancer: The recommended dose of doxorubicin hydrochloride liposome injection is 50 mg/m² intravenously over 60 minutes every 28 days until disease progression or unacceptable toxicity.
AIDS-Related Kaposi's Sarcoma: The recommended dose of doxorubicin hydrochloride liposome injection is 20 mg/m² intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.
Multiple Myeloma: The recommended dose of doxorubicin hydrochloride liposome injection is 30 mg/m² intravenously over 60 minutes on day 4 of each 21-day cycle for eight cycles or until disease progression or unacceptable toxicity. Administer doxorubicin hydrochloride liposome injection after bortezomib on day 4 of each cycle.
Dose Modifications for Adverse Reactions: Do not increase doxorubicin hydrochloride liposome injection after a dose reduction for toxicity. (See Tables 2 and 3.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

For neuropathic pain or peripheral neuropathy, no dosage adjustments are required for doxorubicin hydrochloride liposome injection. Refer to bortezomib manufacturer's prescribing information.
Method of administration: Preparation: Dilute doxorubicin hydrochloride liposome injection doses up to 90 mg in 250 mL of 5% Dextrose Injection, USP prior to administration. Dilute doses exceeding 90 mg in 500 mL of 5% Dextrose Injection, USP prior to administration. Refrigerate diluted doxorubicin hydrochloride liposome injection at 2°C to 8°C (36°F to 46°F) and administer within 24 hours.